IL1B and ductal breast carcinoma in situ: The results of Figure 2 indicate that the incidence of TNFα expression was 50% in DCIS patients and was significantly increased to 85.7% in IDC-with-relapse patients (p = 0.005); Similarly, the incidence of IL-1β was significantly raised from 60% in DCIS to 88.6% in IDC-with-relapse patients (p = 0.017).